Italian biotech and contract manufacturing company ReiThera has opened a 15 million euro ($14.6 million) facility expansion focussed on large-scale viral vectors for vaccines and gene therapies. The debut followed operational approval from the Italian Medicines Agency.

Construction of the 1,500-square-meter facility kicked off in May 2020. The expansion features bioreactors with scaled volume capacities of 200, 1,000 and 2,000 litres.

The facility can accommodate manufacturing based on adenovirus, adeno-associated virus and lentivirus.